Occidental Asset Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,629 shares of the biopharmaceutical company’s stock after purchasing an additional 2,157 shares during the quarter. Occidental Asset Management LLC’s holdings in Gilead Sciences were worth $718,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in GILD. Dimensional Fund Advisors LP grew its stake in Gilead Sciences by 1.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock valued at $320,822,000 after purchasing an additional 51,905 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Gilead Sciences during the 1st quarter worth approximately $2,305,000. CAPROCK Group Inc. lifted its holdings in Gilead Sciences by 14.2% during the 1st quarter. CAPROCK Group Inc. now owns 5,457 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 678 shares during the last quarter. DeDora Capital Inc. lifted its holdings in Gilead Sciences by 29.9% during the 1st quarter. DeDora Capital Inc. now owns 14,632 shares of the biopharmaceutical company’s stock worth $951,000 after buying an additional 3,370 shares during the last quarter. Finally, American National Bank lifted its holdings in Gilead Sciences by 2.0% during the 1st quarter. American National Bank now owns 47,974 shares of the biopharmaceutical company’s stock worth $3,119,000 after buying an additional 929 shares during the last quarter. 78.87% of the stock is currently owned by institutional investors.
In other news, EVP Brett A. Pletcher sold 5,816 shares of Gilead Sciences stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of Gilead Sciences stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total value of $468,504.00. Following the transaction, the executive vice president now owns 34,398 shares in the company, valued at $2,238,277.86. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.
A number of research analysts have commented on the company. Raymond James increased their target price on Gilead Sciences from $83.00 to $86.00 and gave the stock a “strong-buy” rating in a report on Wednesday, July 31st. Credit Suisse Group reduced their target price on Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating on the stock in a report on Wednesday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Jefferies Financial Group set a $95.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Maxim Group set a $84.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $82.29.
Gilead Sciences stock traded down $0.14 during mid-day trading on Thursday, hitting $62.98. 271,972 shares of the company’s stock traded hands, compared to its average volume of 6,220,770. The company has a 50 day moving average price of $66.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. The firm has a market cap of $81.03 billion, a P/E ratio of 10.24, a PEG ratio of 3.04 and a beta of 1.16. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.14. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.91 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.00%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s payout ratio is currently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Elliott Wave Theory
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.